DK3429603T3 - Fremgangsmåder og sammensætninger vedrørende ekspansion af hæmatopoietiske stamceller - Google Patents

Fremgangsmåder og sammensætninger vedrørende ekspansion af hæmatopoietiske stamceller Download PDF

Info

Publication number
DK3429603T3
DK3429603T3 DK17767443.9T DK17767443T DK3429603T3 DK 3429603 T3 DK3429603 T3 DK 3429603T3 DK 17767443 T DK17767443 T DK 17767443T DK 3429603 T3 DK3429603 T3 DK 3429603T3
Authority
DK
Denmark
Prior art keywords
procedures
compositions
expansion
stem cells
hematopoetic stem
Prior art date
Application number
DK17767443.9T
Other languages
English (en)
Inventor
Derrick J Rossi
Wataru Ebina
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Application granted granted Critical
Publication of DK3429603T3 publication Critical patent/DK3429603T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/065—Modulators of histone acetylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
DK17767443.9T 2016-03-15 2017-03-15 Fremgangsmåder og sammensætninger vedrørende ekspansion af hæmatopoietiske stamceller DK3429603T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662308324P 2016-03-15 2016-03-15
US201662309140P 2016-03-16 2016-03-16
PCT/US2017/022534 WO2017161001A1 (en) 2016-03-15 2017-03-15 Methods and compositions relating to hematopoietic stem cell expansion

Publications (1)

Publication Number Publication Date
DK3429603T3 true DK3429603T3 (da) 2022-03-14

Family

ID=59851944

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17767443.9T DK3429603T3 (da) 2016-03-15 2017-03-15 Fremgangsmåder og sammensætninger vedrørende ekspansion af hæmatopoietiske stamceller

Country Status (7)

Country Link
US (1) US20190119642A1 (da)
EP (2) EP4049665A1 (da)
JP (2) JP7080179B2 (da)
AU (1) AU2017235461B2 (da)
DK (1) DK3429603T3 (da)
WO (1) WO2017161001A1 (da)
ZA (1) ZA201806132B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3397756B1 (en) * 2015-12-30 2023-03-08 Novartis AG Immune effector cell therapies with enhanced efficacy
CA3035660A1 (en) 2016-09-06 2018-03-15 The Children's Medical Center Corporation Immune cells derived from induced pluripotent stem cell
GB201618106D0 (en) * 2016-10-26 2016-12-07 Lift Biosciences Ltd Cancer-killing cells
TW201841916A (zh) 2017-04-12 2018-12-01 美商麥珍塔治療學股份有限公司 芳香烴受體拮抗劑及其用途
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
EP3704232A1 (en) * 2017-10-31 2020-09-09 Magenta Therapeutics, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
EP3735412B1 (en) * 2018-01-03 2024-02-21 EdiGene Biotechnology, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
US20210254006A1 (en) 2018-06-06 2021-08-19 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
SG11202011872QA (en) 2018-07-10 2021-01-28 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
WO2020018848A1 (en) * 2018-07-19 2020-01-23 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using amido compounds
KR20210076048A (ko) * 2018-10-12 2021-06-23 라이프 테크놀로지스 코포레이션 조혈 줄기 및 전구 세포 확장 시스템
CN109536447A (zh) * 2018-12-28 2019-03-29 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CN109468277A (zh) * 2018-12-28 2019-03-15 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
WO2020223517A1 (en) * 2019-05-01 2020-11-05 Transfusion Health, Llc Methods of making oligopotent and unipotent precursors
CN110904038B (zh) * 2019-12-13 2023-09-12 深圳市蓝思人工智能医学研究院 一种间充质干细胞及其应用
JP2023506215A (ja) * 2019-12-18 2023-02-15 ウニヴェルシテ ド モントリオール 抗がん性化合物としてのＣｕｌｌｉｎ３アダプタＫＢＴＢＤ４モジュレータ
WO2023101943A1 (en) * 2021-11-30 2023-06-08 Trailhead Biosystems Inc. Methods and compositions for maintaining and expanding hematopoietic stem cells
US20230174938A1 (en) * 2021-12-08 2023-06-08 Trailhead Biosystems Inc. Methods and compositions for generating human erythroid progenitor cells

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH223191A (de) 1942-05-28 1942-08-31 Ramel Otto Vorrichtung zum Betätigen der Bremsen an Fahrrädern.
US2993931A (en) 1958-12-26 1961-07-25 Texaco Inc Process for preparing urea and an aromatic amine
US2997422A (en) 1959-01-09 1961-08-22 Smith Kline French Lab Monoamine oxidase inhibition
US3011945A (en) 1960-03-07 1961-12-05 Smith Kline French Lab Phenylcyclopropylamine -10-(omega-aminoalkyl)-phenothiazine ataractic composition
US3079403A (en) 1960-09-19 1963-02-26 Smith Kline French Lab Process for preparing amines
US3134676A (en) 1961-06-21 1964-05-26 Smith Kline French Lab Animal feed compositions and methods for their administration
US3244596A (en) 1962-10-18 1966-04-05 Univ Iowa College Of Pharmacy Coated medicinal agents and coating compositions therefor
JPS60149520A (ja) 1984-01-13 1985-08-07 Ajinomoto Co Inc 抗腫瘍剤
JPS61176523A (ja) 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
JPH01224381A (ja) 1988-03-04 1989-09-07 Japan Tobacco Inc トリコスタチン酸、トリコスタチンａの新規な合成中間体、及びトリコスタチン酸、トリコスタチンａの製造方法。
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5731424A (en) 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US6124449A (en) 1990-06-11 2000-09-26 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US5512421A (en) 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
IL104369A0 (en) 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ZA945363B (en) 1993-07-21 1995-03-14 Smithkline Beecham Corp Novel compounds
DE69421624T2 (de) 1993-09-17 2000-07-20 Smithkline Beecham Corp Medikamente bindendes protein
US5426196A (en) 1993-12-22 1995-06-20 Glaxo Inc. Synthesis of diaryl methanes
JPH07206670A (ja) 1994-01-14 1995-08-08 Kyowa Hakko Kogyo Co Ltd 免疫抑制剤
US5486534A (en) 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US5547892A (en) 1995-04-27 1996-08-20 Taiwan Semiconductor Manufacturing Company Process for forming stacked contacts and metal contacts on static random access memory having thin film transistors
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
WO1997010822A1 (en) 1995-09-21 1997-03-27 Eli Lilly And Company SELECTIVE β3 ADRENERGIC AGONISTS
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
US6096748A (en) 1996-03-13 2000-08-01 Smithkline Beecham Corporation Pyrimidine compounds useful in treating cytokine mediated diseases
US6235760B1 (en) 1996-03-25 2001-05-22 Smithkline Beecham Corporation Treatment for CNS injuries
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
EP0827946A1 (en) 1996-09-04 1998-03-11 Vrije Universiteit Brussel Inhibitors for the differentiation of cells, in particular hepatic stellate cells
ATE215369T1 (de) 1996-09-05 2002-04-15 Lilly Co Eli Carbazolanaloge als selektive beta3-adrenergische agonisten
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US6806358B1 (en) 1997-12-16 2004-10-19 University Of California San Diego Peptide inhibitor of TGF-β growth factors
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP1060160A2 (en) 1998-02-27 2000-12-20 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs
FR2778337B1 (fr) 1998-05-05 2001-08-31 Inst Nat Sante Rech Med Antagonistes des ligands du recepteur des arylhydrocarbures
GB9809869D0 (en) 1998-05-09 1998-07-08 Medical Res Council Inhibition of protein kinases
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
JP4533534B2 (ja) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
ES2146552B1 (es) 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6602896B1 (en) 1999-04-01 2003-08-05 The Board Of Trustees Of The University Of Arkansas p38MAPK inhibitor and uses thereof
JP4974414B2 (ja) 1999-05-13 2012-07-11 ワイス・ホールディングズ・コーポレイション アジュバント混合製剤
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts GENESIS OF THE RNA INTERFERENCE PATH AS AID OF TARGETED GENTIAN INTERFERENCE
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
CA2407651C (en) 2000-04-27 2013-07-02 Max-Delbruck-Centrum Fur Molekulare Medizin Sleeping beauty, a transposon vector with a broad host range for the genetic transformation in vertebrates
JP2004508049A (ja) 2000-09-01 2004-03-18 藤沢薬品工業株式会社 Ｆｒ９０１２２８物質の製造法
AU2001295026B2 (en) 2000-09-06 2008-04-03 Novartis Vaccines And Diagnostics, Inc. Inhibitors of glycogen synthase kinase 3
US6509318B1 (en) 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
WO2002059285A1 (en) 2000-10-27 2002-08-01 Fred Hutchinson Cancer Research Center Methods for immortalizing cells
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
US20050287128A1 (en) 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
US20050227936A1 (en) 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
CN1951939A (zh) 2001-05-24 2007-04-25 伊莱利利公司 作为药物的新的吡唑衍生物
US20030028905A1 (en) 2001-07-31 2003-02-06 Petra Knaus Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms
ATE468861T1 (de) 2001-08-16 2010-06-15 Univ Pennsylvania Synthese und verwendung von reagenzien für die verbesserte dna-lipofektion und/oder prodrug- und arzneimitteltherapien mit langsamer freisetzung
EP1427726A1 (en) 2001-08-17 2004-06-16 Merck & Co., Inc. Process for preparing 5-sulfonamido-8-hydroxy-1, 6-naphthyridine-7-carboxamides
US20040006030A1 (en) 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of TGF-beta 2 expression
AU2003224335A1 (en) 2002-05-15 2003-12-02 Smithkline Beecham Corporation Benzoxazine and benzoxazinone substituted triazoles
US7190468B2 (en) 2002-07-17 2007-03-13 Hewlett-Packard Development Company, L.P. Background document rendering system and method
JP2005539000A (ja) 2002-07-31 2005-12-22 スミスクライン・ビーチャム・コーポレイション Ａｌｋ５阻害剤としての２−フェニルピリジン−４−イル誘導体
OA12925A (en) 2002-09-18 2006-10-13 Pfizer Prod Inc Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors.
BR0314302A (pt) 2002-09-18 2005-07-05 Pfizer Producs Inc Compostos de pirazol como inibidores do fator de crescimento trnasformante (tgf)
AU2003268155A1 (en) 2002-09-19 2004-04-08 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
EP1418164A1 (en) 2002-11-07 2004-05-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists
US20040138188A1 (en) 2002-11-22 2004-07-15 Higgins Linda S. Use of TGF-beta inhibitors to counteract pathologic changes in the level or function of steroid/thyroid receptors
EP1590347A1 (en) 2003-01-27 2005-11-02 Pfizer Products Inc. Isothiazole derivatives
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
US7189733B2 (en) 2003-03-12 2007-03-13 Millennium Pharmaceuticals, Inc. Compositions and methods for inhibiting TGF-β
JP2006521398A (ja) 2003-03-28 2006-09-21 サイオス・インコーポレーテツド ＴＧＦβの二−環式ピリミジン阻害剤
AU2004226278B2 (en) 2003-04-03 2010-07-29 Merck Patent Gmbh Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor Xa in the treatment of thrombo-embolic diseases
US7575822B2 (en) 2003-04-09 2009-08-18 Bloom Energy Corporation Method of optimizing operating efficiency of fuel cells
EP1633718B1 (en) 2003-06-17 2012-06-06 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-s
JP4723799B2 (ja) 2003-07-08 2011-07-13 株式会社ソニー・コンピュータエンタテインメント 制御システムおよび制御方法
US20060229266A1 (en) 2003-08-13 2006-10-12 Kumar Nalin M Silencing of tgf-beta receptor type II expression by sirna
FR2860514A1 (fr) 2003-10-03 2005-04-08 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
WO2005039570A1 (ja) 2003-10-28 2005-05-06 Riken ＴＧＦ－β情報伝達経路阻害剤
EP1723146A1 (en) 2004-03-01 2006-11-22 Eli Lilly And Company Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms
FR2873498B1 (fr) 2004-07-20 2007-08-10 Conception & Dev Michelin Sa Arret d'une pile a combustible alimentee en oxygene pur
JP2007176795A (ja) 2004-08-18 2007-07-12 Univ Nihon ＴＧＦ−β遺伝子発現抑制剤
DE102004047254A1 (de) 2004-09-29 2006-04-13 Merck Patent Gmbh Carbonylverbindungen
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
US20070066632A1 (en) 2005-03-25 2007-03-22 Scios, Inc. Fused bicyclic inhibitors of TGFbeta
US20080207594A1 (en) 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
BRPI0613639A2 (pt) 2005-07-22 2012-02-22 Lilly Co Eli composto, composição farmacêutica, uso do composto, e, processo para produzir um composto
WO2007016485A2 (en) 2005-07-29 2007-02-08 Athersys, Inc. Use of a gsk-3 inhibitor to maintain potency of cultured cells
WO2007039151A1 (en) 2005-09-28 2007-04-12 Universität Zürich Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases
US8021867B2 (en) 2005-10-18 2011-09-20 Duke University Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity
JP5112322B2 (ja) 2005-10-24 2013-01-09 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ 免疫応答調節剤の製造におけるＴＧＦ−β１インヒビターペプチドの使用
JP2009513698A (ja) 2005-10-31 2009-04-02 デウン ファーマシューティカル カンパニー リミテッド 新規な抗菌トリアゾール誘導体
EP1801098A1 (en) 2005-12-16 2007-06-27 Merck Sante 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
KR20080082618A (ko) 2005-12-16 2008-09-11 알콘, 인코퍼레이티드 Ａｌｋ5 조절제를 사용한 안압의 조절
WO2007075911A2 (en) 2005-12-22 2007-07-05 Yale University Inhibition of glycogen synthase kinase and methods of treating autoimmune or immune inflammatory disease
CA2637392A1 (en) 2006-01-23 2007-07-26 Crystalgenomics, Inc. Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same
EP1992360A4 (en) 2006-02-01 2010-02-17 Univ Tokyo USE IN ASSOCIATION OF A TGF-BETA SIGNAL INHIBITOR AND ANTITUMMER AGENT
ITMI20060181A1 (it) 2006-02-03 2007-08-04 Univ Padova Modulatori del tgf-b e loro uso
US7846908B2 (en) 2006-03-16 2010-12-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of TGF-beta and therapeutic uses thereof
RU2493252C2 (ru) 2006-03-24 2013-09-20 Чилдрен'З Медикал Сентер Корпорейшн Способ стимулирования экспансии гематопоэтических стволовых клеток
WO2008022182A1 (en) 2006-08-16 2008-02-21 The Uab Research Foundation Methods for promoting coupling between bone formation and resorption
EP1995316A1 (de) 2007-05-25 2008-11-26 Qiagen GmbH Verfahren zur schonenden Zellaufreinigung, Zellgewinnung und Transfektion von Zellen
EP2009095A1 (en) 2007-06-28 2008-12-31 Innovalor AG Method of generating glucose-responsive cells
JP2010538003A (ja) 2007-08-29 2010-12-09 グラクソスミスクライン エルエルシー チアゾールおよびオキサゾールキナーゼ阻害薬
AU2008318430A1 (en) 2007-10-31 2009-05-07 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
GB0805312D0 (en) 2008-03-20 2008-04-30 Medical Res Council Modulation of the immune response
FR2932180B1 (fr) 2008-06-04 2012-08-10 Centre Nat Rech Scient Dihydro iso ca-4 et analogues : puissants cytotoxiques, inhibiteurs de la polymerisation de la tubuline
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
GB0818907D0 (en) 2008-10-15 2008-11-19 Isis Innovation Histone lysine demethylase inhibitors
US9468649B2 (en) 2008-12-05 2016-10-18 The Regents Of The University Of California Methods of treating epilepsy with transforming growth factor beta inhibitors
CA2747398C (en) 2008-12-17 2023-06-20 The Scripps Research Institute Generation and maintenance of stem cells
WO2010085699A2 (en) 2009-01-23 2010-07-29 The Johns Hopkins University Mammalian piggybac transposon and methods of use
US20120122212A1 (en) 2009-03-06 2012-05-17 Marica Grskovic Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells
US8822684B1 (en) 2009-08-06 2014-09-02 Vanderbilt University Compounds and methods useful for directing stem cell differentiation
US9186337B2 (en) 2010-02-24 2015-11-17 Oryzon Genomics S.A. Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
CA2804795A1 (en) 2010-07-12 2012-01-19 Nicholas Vrolijk Romidepsin solid forms and uses thereof
US20140163041A1 (en) 2011-02-08 2014-06-12 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
AU2012214419B2 (en) 2011-02-09 2015-12-24 Glaxosmithkline Llc Lyophilized formulations
WO2012115120A1 (ja) 2011-02-21 2012-08-30 国立大学法人 大阪大学 ５－ｈｔ神経細胞の製造方法
WO2012122405A2 (en) 2011-03-08 2012-09-13 The Trustees Of Columbia University In The City Of New York Screening assays using stem cells and stem cell-derived neurons from mouse models of alzheimer's disease
RU2456356C1 (ru) 2011-04-29 2012-07-20 Борис Сергеевич Кустов Коллоидный раствор наносеребра и способ его получения
WO2013016452A2 (en) 2011-07-25 2013-01-31 Vanderbilt University Cancer treatment using bmp inhibitor
EP2763670B1 (en) 2011-10-03 2018-12-05 Universite Libre De Bruxelles Reactivation of hiv-1 gene expression to treat persistent hiv infection
US8735622B2 (en) 2011-11-30 2014-05-27 The Regents Of The University Of Colorado, A Body Corporate Histone demethylase inhibitors and methods for using the same
WO2013086436A1 (en) 2011-12-08 2013-06-13 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
CA2863291A1 (en) 2012-01-12 2013-07-18 Celgene Corporation Romidepsin formulations and uses thereof
WO2013110198A1 (en) 2012-01-27 2013-08-01 Université de Montréal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
MX368315B (es) 2012-04-24 2019-09-27 Int Stem Cell Corporation Derivación de células madre neurales y neuronas dopaminérgicas a partir de células madre pluripotentes humanas.
WO2013166488A1 (en) 2012-05-04 2013-11-07 Indiana University Research & Technology Corporation Methods for generating the inner ear and other cranial placode-derived tissues using pluripotent stem cells
WO2014018375A1 (en) 2012-07-23 2014-01-30 Xenon Pharmaceuticals Inc. Cyp8b1 and uses thereof in therapeutic and diagnostic methods
CN103577266B (zh) 2012-07-31 2017-06-23 国际商业机器公司 用于对现场可编程门阵列资源进行分配的方法及系统
US20150267174A1 (en) 2012-10-09 2015-09-24 Nakanobu Hayashi Reprogramming peptide and use thereof
SG11201503045YA (en) 2012-10-19 2015-05-28 Agency Science Tech & Res Methods of differentiating stem cells into one or more cell lineages
US20140127231A1 (en) 2012-11-02 2014-05-08 University Of Vermont p38 MAPK Pathway Inhibitors as Female-Specific Therapeutics
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014102731A1 (en) 2012-12-31 2014-07-03 Leiutis Pharmaceuticals Pvt. Ltd Novel pharmaceutical compositions of romidepsin
US20140248696A1 (en) 2013-03-01 2014-09-04 Wisconsin Alumni Research Foundation Methods of maintaining, expanding, and diffrentiating neuronal subtype specific progenitors
JP2016510745A (ja) 2013-03-04 2016-04-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害剤およびその使用方法
JP6276378B2 (ja) 2013-03-14 2018-02-07 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
JP2016513974A (ja) * 2013-03-14 2016-05-19 チルドレンズ メディカル センター コーポレーション 造血幹細胞系列を初期化するための組成物および方法
CA2910394A1 (en) 2013-04-26 2014-10-30 Memorial Sloan-Kettering Cancer Center Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells
WO2014194280A2 (en) 2013-05-30 2014-12-04 The Board of Regents of the Nevada System of Higher Education on behalf of the University of Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells
EP3020803B1 (en) 2013-06-11 2020-03-11 Kyoto University Method for producing renal precursor cells
WO2014205266A2 (en) 2013-06-20 2014-12-24 The Broad Institute Compositions and methods for detecting and treating glioblastoma
CN104278008B (zh) 2013-07-12 2020-08-21 北京宏冠再生医学科技有限公司 一种通过小分子化合物处理来制备多潜能干细胞的方法、试剂盒和用途
JP2017511132A (ja) * 2014-03-26 2017-04-20 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法
WO2016210292A1 (en) * 2015-06-25 2016-12-29 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance

Also Published As

Publication number Publication date
AU2017235461B2 (en) 2023-02-23
EP3429603B1 (en) 2021-12-29
AU2017235461A1 (en) 2018-09-27
JP7080179B2 (ja) 2022-06-03
JP2019508055A (ja) 2019-03-28
WO2017161001A1 (en) 2017-09-21
EP3429603A4 (en) 2019-10-23
US20190119642A1 (en) 2019-04-25
JP2022081617A (ja) 2022-05-31
ZA201806132B (en) 2019-12-18
EP3429603A1 (en) 2019-01-23
EP4049665A1 (en) 2022-08-31

Similar Documents

Publication Publication Date Title
DK3429603T3 (da) Fremgangsmåder og sammensætninger vedrørende ekspansion af hæmatopoietiske stamceller
DK3445838T3 (da) Isolering af planteekstrakter
DK3601533T3 (da) Fremgangsmåder til frembringelse af tumorinfiltrerende lymfocytter og anvendelser af samme i immunoterapi
DK3595653T3 (da) Sammensætninger af plinabulin og anvendelse heraf
DK3356529T3 (da) Sammensætninger og fremgangsmåder til hæmning af genekspression af lpa
DK3303317T3 (da) Fremgangsmåder og sammensætninger til inhibering af interaktionen af menin med MLL-proteiner
DK3212778T3 (da) Fremgangsmåder og sammensætninger til stabilisering af trans-splejsning af intein-modificerede proteaser
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3685848T3 (da) Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3509581T3 (da) Formuleringer af (r)-2-amino-3-phenylpropylcarbamat
DK3668851T3 (da) Fremgangsmåde til fremstilling af thiocarbonater
DK3288553T3 (da) Kombinationer af cannabinoider og n-acylethanolaminer
DK3574135T3 (da) Fremgangsmåde og formulering til fremstilling af ligninfibre
DK3467904T3 (da) Separator med høj vådbarhed og fremgangsmåde til fremstilling deraf
DK3349772T3 (da) Fremgangsmåde til fremstilling af urteekstrakter
DK3370949T3 (da) Sammensætning af tætningsmiddel
DK3280839T3 (da) Indretning til fremføring og spredning af stofstykker
DK3265555T3 (da) T-celle-ekspansion
DK3286300T3 (da) Isolering af bona fide pankreatiske stamceller
DK3514227T3 (da) Fremgangsmåde til fremstilling af tredimensionel cellestruktur og støtte anvendt til samme
DK3451836T3 (da) Sammensætninger af saponiner og planteekstrakter
DK3200748T3 (da) Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted
DK3347342T3 (da) Fremgangsmåde til fremstilling af biguanidin-salte og s-triaziner
DK3265126T3 (da) Kombinationsformulering af tesofensin og metoprolol